Legal Representation
Attorney
Nicole K. McLaughlin, Esquire
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 12, 2018 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Mar 12, 2018 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 13, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 11, 2017 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jul 11, 2017 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jul 11, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 7, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 13, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 13, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 23, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 4, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Nov 3, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 19, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 18, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 18, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 18, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 17, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 17, 2016 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 17, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 14, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 12, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 9, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development in the fields of pharmaceuticals, biopharmaceuticals and therapeutics; research and development in the field of personalized medicine and its delivery to patients; research and development in the field of oncology; research and development of personalized cancer treatments
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"